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To The ediTor
Recently, Lin and colleagues have reported a case of 
pyridoxine-dependent seizures in this journal1. The diag-
nosis was based upon the clinical criteria as formulated by 
Baxter2. In discussing the case the authors state that the 
underlying pathophysiology of the disorder is unknown 
and that no biochemical aids are available in establishing 
the diagnosis.
Indeed, for 50 years pyridoxine dependent epilepsy 
has been a clinical diagnosis based on the clinical effect 
of pyridoxine and confirmation of the diagnosis by a trial 
of pyridoxine withdrawal. However, in 2006 mutations in 
the ALDH7A1 gene have been found in patients with pyr-
idoxine-dependent seizures3. Since then, mutations with-
in this gene have been shown to be present in the ma-
jority of patients with a clinical diagnosis of pyridoxine-
dependent seizures3-6. These mutations cause a deficien-
cy in α-aminoadipic semialdehyde (α-AASA) dehydroge-
nase, indirectly leading to a secondary deficiency in pyri-
doxal-5-phosphate (P5P), which causes seizures. Adminis-
tration of pyridoxine restores the P5P pool, thus control-
ling seizure activity3. 
Another consequence of α-AASA dehydrogenase de-
ficiency is an accumulation of α-AASA within the body, 
leading to increased plasma and cerebrospinal fluid lev-
els3. α-AASA is excreted in the urine, thus leading to highly 
increased urinary levels in pyridoxine dependent patients 
with ALDH7A1 mutations. We and others have shown that 
urinary α-AASA should be used as the biomarker for pyri-
doxine dependent seizures3-5,7.
In conclusion, in contrast to what Lin and co-authors 
have stated, the underlying pathophysiology and genetic 
mutations can be determined in the vast majority of pa-
tients with pyridoxine-dependent seizures. The diagno-
sis is no longer merely dependent on clinical criteria, but 
can be confirmed at the metabolite level by measuring α-
AASA in the urine of suspected patients. Ideally, urinary 
α-AASA quantification and, if the biomarker is increased, 
subsequent DNA analysis should be performed in any 
child with suspected pyridoxine-dependent seizures. A 
trial of withdrawal in these patients should be omitted7.
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The AuTors’ reply
We read with great interest and appreciate the com-
ments made by Dr. Jasper V. Been et. al. about our arti-
cle “pyridoxine-dependent epilepsy initially responsive 
to phenobarbital”1. In his letter, Dr. Jasper called our at-
tention about the mutation in the ALDH7A1 gene as the 
cause of pyridoxine-dependent seizures.
In 2006 Mills et al. has conducted the initial studies 
concerning the mutations in ALDH7A1. In his work, the hu-
man gene ALDH7A1 was identified and mapped to locus 
5q31 (the locus of pyridoxine dependent epilepsy). This 
gene encodes antiquitin that has aldehyde dehydrogenase 
activity and when mutations occur, it abolishes the activ-
ity of antiquitin as a D1-piperideine-6-carboxylate (P6C) 
– α-aminoadipic semialdehyde (α-AASA) dehydrogenase. 
The accumulating P6C inactivates pyridoxal 5’-phosphate 
(PLP) a cofactor essential for normal metabolism of neu-
rotransmitter2.
Sequencing of ALDH7A1 from individuals with pyri-
doxine dependent seizures (PDS) revealed homozygous 
and heterozygous mutations that were not detected in 
control subjects2.
MuTATions in The ALDH7A1 Gene cAuse 
pyridoXine-dependenT seiZures
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In the following years, the pathogenesis of PDS were 
further detailed, specially in 2007 when Plecko et al. re-
ported the ALDH7A1 mutational analysis in 18 patients 
with PDS3 and Kanno et al. revealed point mutation in re-
gions of the ALDH7A1 gene in 4 out of 5 patients with PDS4.
Those articles also reported that α-AASA dehydroge-
nase deficiency is characterized by increases in α-AASA in 
urine, plasma and cerebrospinal fluid3,4. Further, Bok et al., 
measuring α-AASA in urine and plasma by liquid chroma-
tography-tandem mass spectroscopy in 12 Dutch clinical-
ly diagnosed patients with PDS revealed that α-AASA was 
elevated in both urine and plasma in 10 patients5.
The information provided by those reports culminat-
ed in the statement by Dr. Jasper that quantification of 
the urinary α-AASA should be used as a biomarker of PDS, 
that, ideally, DNA analysis should be performed in any 
child with suspected PDS, and that a pyridoxine trial of 
withdrawal should be omitted.
The information brought by those articles concerning 
the pathogenesis of PDS is irrefutable. Unfortunately, the 
reports of Kanno et al.4; Bok et al.5 and the letter of Struys 
et al.6 were published, in their final form, few months after 
the submission of our article. Also unfortunately, the sem-
inal articles of Mills et al.2 and Plecko et al.3 failed to be 
brought to our knowledge leading to inadvertent and un-
intentional un-accuracy in our article regarding the patho-
physiology of PDS.
The statement that the pyridoxine-withdrawal test for 
making a definitive diagnosis of PDS should be replaced 
by DNA analysis and biochemical tests detecting urinary 
α-AASA should, however, be considered with care. It must 
be taken into account that DNA analysis and diagnostic 
biochemical tests are not available or are not affordable 
in many countries. It also must be taken into account that 
PDS leading to neonatal status epilepticus is an emergency 
and when there is a clinical and electroencephalography 
suspicious of PDS, pyridoxine must be given. Therefore, in 
places where the ideal situation cannot be achieved, the 
final diagnosis may only be possible in the traditional and 
in the readily available way.
This point of view is shared by Kumar et al.7 that sus-
tain that pyridoxine withdrawal test, wherein pyridoxine is 
withheld from a suspected PDS patient to observe recur-
rence of seizures that respond to pyridoxine is considered 
to be the gold standard for the diagnosis of PDS. He goes 
further when proposing that in families where the parents 
are not convinced about the need for life-long pyridox-
ine therapy, consideration should be given to undertak-
ing an early “pyridoxine withdrawal test”. This, according 
to his opinion, in addition to making a definitive diagno-
sis of PDS for the physician, also demonstrates the need 
for continuing pyridoxine therapy to the parents, thereby 
guarding against the possibility of loss to follow-up7.
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